Many breast cancer clinical trials using immunotherapy combined with chemotherapy or other targeted agents have mostly been in TNBC and HER2+ tumors as these subtypes display the highest immunogenicity (PD-L1+ TIL, PD-L1+ tumor, mutation, neoantigen load, and MHC expression) [34]. Here, CD274 is linked to neoplasm.